ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
N9831 trial: genes associated with early and late recurrence in HER2+ breast cancer
The late recurrence of ER+ breast cancer
Anthracycline benefit in early HR+/HER2- breast cancer
The evolution of HER2-low breast cancer from primary to recurrence
Reducing the Risk of Recurrence In HR+/HER2- Early Breast Cancer Requires Action: MDT Clinical Ca...
Important considerations in the management of HR+, HER2-negative early breast cancer
How to Understand Late Recurrence of Hormone Receptor-Positive Breast Cancer
Optimizing treatment in patients with early-stage HER2-positive breast cancer
Dr. McCann on Prognosis for Patients With HER2-Positive Breast Cancer
Key challenge associated with the management of HR+/HER2- breast cancer
What's the Best Diet for Hormone Receptor-Positive Breast Cancer? The Ultimate Guide for HR+
Foundation Frontiers: Advanced Breast Cancer - Updates to HR+/HER2- Treatment Landscape
A 52-Year-Old Woman With HER2-Positive Breast Cancer
Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors
Management of premenopausal HR+/HER2- breast cancer with micro-metastasis
Prognosis of a HER2+ Breast Cancer Patient
Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast Cancer
Circulating tumour cells may predict late recurrence in HR-positive breast cancer patients
Dr. Mamounas on Recurrence Rates in Breast Cancer
